NCT00430833

Brief Summary

The primary hypothesis of the study is that treatment with AT1-R antagonist in patients with nonobstructive form of HCM will be first save, second will cause regression of myocardial hypertrophy.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 31, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 2, 2007

Completed
Last Updated

February 2, 2007

Status Verified

January 1, 2007

First QC Date

January 31, 2007

Last Update Submit

January 31, 2007

Conditions

Hypertrophic Cardiomyopathy

Interventions

candesartanDRUG

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • HCM defined on the basis of echocardiographic criteria showing a nondilated, hypertrophied left ventricle (any wall thickness \> 15 mm) in the absence of known causes of LV hypertrophy hypertension or valvular disease

You may not qualify if:

  • Hypertrophic obstructive cardiomyopathy defined as presence of resting gradient in left ventricular outflow tract ³30 mmHg or in righ ventricular outflow tract ³15 mmHg at Doppler echocardiography;
  • Atrial fibrillation;
  • Treatment with ACE inhibitors or AT1-R antagonists any time in the past;
  • Contraindications to AT1-R antagonists;
  • Coronary artery disease, renal failure, hepatic disorders or serious intercurrent illness limiting survival; and
  • Poor echocardiographic image quality.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cardiocenter, Third Faculty of Medicine, Charles University

Prague, 10034, Czechia

Location

Related Publications (1)

  • Penicka M, Gregor P, Kerekes R, Marek D, Curila K, Krupicka J; Candesartan use in Hypertrophic And Non-obstructive Cardiomyopathy Estate (CHANCE) Study Investigators. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. J Mol Diagn. 2009 Jan;11(1):35-41. doi: 10.2353/jmoldx.2009.080082. Epub 2008 Dec 12.

    PMID: 19074594DERIVED

MeSH Terms

Conditions

Cardiomyopathy, Hypertrophic

Interventions

candesartan

Condition Hierarchy (Ancestors)

CardiomyopathiesHeart DiseasesCardiovascular DiseasesAortic Stenosis, SubvalvularAortic Valve StenosisAortic Valve DiseaseHeart Valve Diseases

Study Officials

  • Martin Penicka, PhD

    Charles University, Prague, Czech Republic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 31, 2007

First Posted

February 2, 2007

Last Updated

February 2, 2007

Record last verified: 2007-01

Locations

CZ(1)